To investigate the effects of leptin on platelet aggregation and platelet free calcium (Ca 2+ ) concentrations, and the role of the long form of leptin receptor (ObRb) and the phospholipase C (PLC) in mediating leptin effects on platelet function. DESIGN: Cross-sectional, clinical study. SETTING: Outpatient's Service for Prevention and Treatment of Obesity at the University Hospital of Messina, Italy. SUBJECTS: A total of 19 healthy, 14 overweight, and 16 obese male subjects. MEASUREMENTS: ADP-induced platelet aggregation and platelet Ca 2+ were measured after incubation of platelet-rich plasma with leptin alone 5-200 ng/ml, leptin 200 ng/ml and anti-human leptin receptor long-form antibody (ObRb-Ab) 5-10 ml, or leptin 200 ng/ml and PLC inhibitor U73122 0.5-1 nmol/l. RESULTS: Platelet stimulation with leptin lead to a significant and dose-dependent increase in platelet aggregation in healthy subjects. This effect was blunted in overweight, and strongly reduced in obese subjects. Similarly, the incubation with leptin induced a significant and dose-dependent increase in platelet free calcium, which was blunted in overweight and obese patients. The effect of leptin on platelet aggregation and platelet Ca 2+ was completely abated by the anti-ObRb-Ab and the PLC inhibitor U73122. CONCLUSIONS: Leptin produces a dose-dependent enhancement of ADP-induced platelet aggregation in humans. Platelet aggregation response to leptin is blunted, but not completely abolished in overweight/obese subjects, thus suggesting that platelet may represent a site of leptin resistance in human obesity. Leptin increases platelet free calcium in a dose-dependent manner. The inhibition of PLC completely abates the effect of leptin on both platelet aggregation and Ca 2+ levels. These findings suggest that signaling pathway other than JAK-STAT tyrosine phosphorylation (ie PLC and calcium) may be involved in mediating the prothrombotic action of leptin.
Introduction
Obesity is known to be associated with accelerated atherothrombosis and increased incidence of cardiovascular morbidity and mortality. Evidences suggest that metabolic disorders that frequently accompany excess body weight, such as insulin resistance, hypertension, hypertriglyceridemia, and decreased HDL cholesterol, promote the progression of atherosclerosis in obese patients. [1] [2] [3] Additionally, altered hemostatic balance also may contribute to the excess risk of acute cardiovascular events in obese individuals. 4, 5 Leptin, the product of the ob gene, 6 is a protein mainly secreted by the adipose tissue that signals the size of energy stores to the central nervous system, thus affecting hypothalamic centres involved in the regulation of food-intake and energy balance. 7 Although leptin's major role seems to be in the regulation of body weight and energy metabolism, several evidences suggest that this hormone could be involved in other pathophysiological mechanisms. Leptin has been reported to regulate immune function, angiogenesis, bone formation, and fertility, and expression of leptin receptor has been demonstrated in a variety of tissues. [8] [9] [10] [11] [12] [13] In the last few years, it has been suggested that leptin may play a relevant role in the association between obesity and cardiovascular risk, 14 and a recent report of the West of Scotland Coronary Prevention (WOSCOP) Study showed that leptin is an independent risk factor for coronary heart disease. 15 The long form of leptin receptor (ObRb) has been found on platelet membrane, and it has been suggested that leptin may promote the aggregation of human platelets through the activation of its receptor. 16 The ability of leptin to enhance platelet aggregation has been recently confirmed in ob/ob mice 17 and healthy subjects. 18 At variance, Ozata et al failed to find any effect of leptin on ADP-, collagen-and epinephrine-induced platelet aggregation, in both healthy and obese subjects, and in leptin-deficient men. 19 Thus, the effect of leptin on platelet aggregation is a controversial issue. Furthermore, the postreceptorial mechanisms involved in the prothrombotic action of leptin are still to be elucidated.
The purpose of the present study was to investigate: (1) the effects of leptin on platelet aggregation in healthy, overweight and obese subjects; (2) the effects of leptin on platelet-free calcium (Ca 2+ ) concentrations; and (3) the role of the ObRb and the phospholipase C (PLC) in mediating leptin effects on platelet function.
Methods
After obtaining their written informed consent, 19 healthy, 14 overweight, and 16 obese male subjects were enrolled in the study. All subjects underwent a complete clinical and laboratory assessment to exclude major health problems other than overweight/obesity. To participate in the study all subjects were requested not to take drugs in the 4 weeks before sampling.
Subjects with body mass index (BMI) values lower than 25 kg/m 2 were considered normal weight; subjects with BMI 25-30 kg/m 2 were considered overweight; subjects with BMI greater than 30 kg/m 2 were considered obese. 20 Waist and hip circumferences were measured, and the waist-to-hip ratio (WHR) was then calculated.
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In all subjects, after an overnight fasting, a venous blood sample was obtained in the supine position from the cubital vein of the arm using a cannula that had been placed 30 min before sampling to avoid the stress of venipuncture, and maintained by slow infusion of saline solution (0.5 ml/min). For platelet study, blood samples (25 ml) were collected in a conical polipropylene tube containing 3.33 ml/l of ACD (consisting of 64 mmol/l citric acid, 85 mmol/l sodium citrate and 111 mmol/l dextrose). An aliquot (5 ml) was separately collected in ACD, and plasma obtained by centrifugation was used for the assay of plasma glucose (AutoAnalyzer, Beckman, Milan, Italy), insulin ( To compare platelet aggregation in healthy, overweight, and obese subjects, platelet suspension (1 ml) was stimulated by the addition of ADP (Sigma Chemical Co, St Louis, MO, USA) 10 mmol/l. To study leptin effects on ADP-induced platelet aggregation, platelet suspension was preincubated with leptin 5-200 ng/ml (Linco Research Inc, St Charles, MO, USA) for 5 min, and then stimulated by the addition of ADP 2 mmol/l.
Platelet Ca 2+ concentrations were measured before and after incubation of platelet suspension with leptin 5-200 ng/ ml for 30 min. To investigate whether the effects of leptin on platelet aggregation and Ca 2+ concentrations were mediated by the ObRb, platelets were preincubated with leptin alone (50-200 ng/ml) or leptin 200 ng/ml and anti-human leptin receptor long-form antibody (ObRb-Ab) 5-10 ml (Linco Research Inc, St Charles, MO, USA). To investigate the role of PLC in mediating leptin effects on platelet aggregation and Ca 2+ levels, platelets were preincubated with leptin alone (50-200 ng/ml) or leptin 200 ng/ml and PLC inhibitor U73122 (Calbiochem, San Diego, CA, USA) (0.5-1 nmol/l). After each incubation, the suspension was centrifuged at 2000 rpm for 10 min at room temperature and the pellet was resuspended in 1 ml HBS.
Statistical analysis
Analysis was performed using ANOVA one-way test with Scheffé post hoc test for multiple comparisons. Data were expressed as mean 7s.e.m. Two-tailed values of Po0.05 were considered statistically significant. All statistical procedures were performed using SPSS V 10.0 statistical software package (SPSS Inc, Chicago, IL, USA).
Results
General characteristics of the subjects studied are summarized in Table 1 . As expected, plasma concentrations of insulin and leptin were significantly increased in both
Leptin and platelet aggregation A Corsonello et al overweight and obese groups with respect to healthy controls. Furthermore, platelet aggregation induced by ADP 10 mmol/l was higher in overweight and obese patients. The effect of preincubation with leptin on ADP-induced platelet aggregation is shown in Figure 1 . Platelet stimulation with leptin led to a significant and dose-dependent increase in platelet aggregation in healthy subjects. Although still present, this effect was blunted in overweight subjects, where only the highest concentrations of leptin (50-200 ng/ml) were able to increase ADP-induced platelet aggregation. In obese subjects, the prothrombotic effect of leptin was strongly reduced and leptin concentrations of 100-200 ng/ml were needed to produce a significant increase in platelet aggregation response. Figure 2 shows the effects of leptin (5-200 ng/ml) on platelet Ca 2+ concentrations. The incubation with leptin induced a significant and dose-dependent increase in platelet-free calcium, which was slightly reduced in overweight patients. Similar to that observed in platelet aggregation study, the ionophoric effect of leptin was strongly reduced in obese subjects and the rise in platelet Ca 2+ concentrations reached the statistical significance level only when platelets were incubated with leptin 200 ng/ml. 
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In order to investigate whether leptin effects on platelet aggregation was mediated by the activation of the ObRb on platelet membrane, we measured platelet aggregation after preincubation with leptin alone or in combination with the ObRb-Ab, and we found that the antibody against the ObRb was able to abolish leptin effect on platelet aggregation. Similar results were obtained when platelet suspensions were preincubated with leptin in combination with the inhibitor of PLC U73122 (Figure 3) .
Finally, we studied the effect of ObRb-Ab or U73122 on leptin-induced increase in platelet Ca 2+ concentration, and we found that the ionophoric effect of leptin was completely abated by the coincubation with ObRb-Ab (5-10 ml) or U73122 (0.5-1 nmol/l) ( Figure 4 ).
Discussion
Platelet activation is known to be involved both in the early and advanced stages of atherosclerosis. 22 In agreement with previous studies, 19, 23 we found increased platelet aggregation response to ADP in overweight and obese subjects with respect to normal weight controls. Rising evidences suggest that leptin may contribute to the development of cardiovascular complications from obesity in humans. 14, 15 Thus, the study of leptin effects on platelet function may provide new insights into the mechanisms linking obesity and cardiovascular diseases.
Our results confirm that leptin is able to potentiate platelet aggregation response to known agonists in healthy subjects. Platelets recently were shown to express the ObRb, and it has been demonstrated that the activation of platelet ObRb is directly coupled to the activation of Janus kinase (JAK) and signal transducer and activator of transcription (STAT) proteins, with a consequent activation of tyrosine phosphorylation. 16 Similarly, a significant enhancement of platelet aggregation response to ADP has been shown in ob/ob, but not in db/ db (ie leptin-receptor deficient) mice. 17 This finding allowed us to hypothesize that platelet aggregation response to leptin stimulation may be different among subjects with different BMI (ie different grades of leptin resistance). We tried to verify this hypothesis by investigating platelet aggregation response to leptin in overweight and obese patients, and we found that the effect of leptin preincubation on platelet aggregation was blunted in overweight subjects, and was strongly reduced in platelets from obese patients, where leptin concentrations of 100-200 ng/ml were needed to produce a significant increase in platelet aggregation response. It is known that most obese humans have elevated plasma leptin concentrations, and it can be assumed that obesity is associated with resistance to leptin action. 24 Recent studies provided evidence that one component of leptin resistance might be an impaired delivery of leptin to its sites of action in the hypothalamus, possibly through a defect in the transport system in the blood-brain barrier, and/or an inhibition of leptin signaling at the hypothalamus by inhibitors such as SOCS-3. 25, 26 Our results demonstrate, for the first time, that leptin-induced platelet aggregation is reduced, but not completely abolished, in overweight and obese patients, thus suggesting that leptin receptor on platelet membrane may represent a site of leptin resistance in human obesity. 
Controls

Leptin and platelet aggregation A Corsonello et al
The findings of the present study are in contrast with a recent report showing that leptin does not affect platelet aggregation in obese and leptin-deficient subjects. 19 The actual level of knowledge in this field does not allow us to explain this discrepancy. In fact, a 1994-2002 Medline research enabled us to find only three studies 16, 17, 19 investigating the role of leptin in the regulation of platelet aggregation. However, we here demonstrate that platelet aggregation induced by ADP 10 mmol/l is higher, while platelet response to leptin preincubation is blunted in overweight and obese subjects. These data seem to be in agreement with the hypothesis by Ozata et al 9 suggesting
that factors other than leptin, such as b-thromboglobulin, platelet factor-4, P-selectin, surface expression of lysosomal or granule proteins, and impaired insulin-mediated antiaggregating activity owing to insulin resistance may be involved in the pathophysiology of enhanced platelet response to agonists in human obesity. 27, 28 On the other hand, the interactions between leptin and these factors in the regulation of platelet function are still unknown, and this issue certainly need further investigations.
Another important finding of this study is that leptin is able to affect platelet-free calcium concentrations. Intraplatelet Ca 2+ is known to represent an important step in platelet functional changes leading to platelet activation. Platelet agonists can induce a rise in cytosol Ca 2+ levels: (1) by activating PLC and the consequent formation of inositol 1,4,5 triphosphate (IP 3 ), which promotes Ca 2+ release from intracellular stores in the cytosol; (2) by inducing an influx of Ca 2+ from the extracellular space. 29, 30 Our study shows that the stimulation of the ObRb on platelet membrane leads to a dose-dependent increase in platelet-free calcium concentration, which is blunted in overweight/obese subjects, and is completely abated by the coincubation with the ObRb antibody. This finding, together with the recent demonstration that leptin is able to cause a sustained increase in intracellular calcium in cultured porcine adrenal medullary chromaffin cells through the activation of the ObRb receptor, 31 suggests that changes in platelet-free calcium concentrations may be involved in platelet response to leptin stimulation. Additionally, the block of PLC by the inhibitor U73122 was able to abolish the effect of leptin on platelet aggregation and free calcium in our study. The activation of PLC is a key early component in the stimulation of several cell types, including platelets, that leads to the hydrolysis of phosphatidylinositol 4,5 diphosphate which, in turn, results in the formation of 1,2-diacylglycerol (DAG) and IP 3 : 32, 33 DAG is known to stimulate protein kinase C (PKC), 34 and IP 3 is able to mobilize intracellular calcium. 35 Together these messengers act in synergy to induce platelet activation including aggregation, secretion of a-and dense-granule contents, formation of thromboxan A 2 (TXA 2 ), and expression of adhesive receptors. 32, 33, 36 Although the effect of the stimulation of the ObRb is mainly mediated by the JAK-STAT signaling system, 37 mounting evidences suggest that pathways other than JAK-mediated STAT proteins tyrosine phosphorylation may be involved in mediating leptin effects at the postreceptorial level. Indeed, it has been shown that mitogen-activated proteine kinases (MAPKs), cyclic adenosine monophosphate (cAMP), activation of voltage-dependent calcium channels, and mobilization of intracellular calcium stores through the activation of PLC may be involved in mediating intracellular leptin effects, 31,38-40 thus suggesting the existence of a complex network of second messengers working for the intracellular transmission of leptin message. Our results are in agreement with this hypothesis, and suggest that the activation of PLC is required for leptin to increase platelet-free calcium concentrations and to potentiate platelet aggregation response to the agonist. In the light of these findings, we propose the following model for the effect of leptin on platelet aggregation: the binding of leptin to the ObRb on platelet membrane causes stimulation of the JAK-STAT pathway, as well as activation of PLC with consequent hydrolysis of phosphatidylinositol 4,5 diphosphate and formation of DAG and IP 3 . DAG activates protein kinase C (PKC), while IP 3 mobilizes intraplatelet Ca 2+ stores. Together these messengers promote platelet aggregation ( Figure 5 ).
In conclusion, the present study confirms that leptin is able to produce a dose-dependent enhancement of ADPinduced platelet aggregation in humans through the activation of the long form of its receptor. Furthermore, we here demonstrate that platelet aggregation response to leptin is blunted but not completely abolished in overweight/obese subjects, thus suggesting that platelet may represent a site of leptin resistance in human obesity. Finally, we show that Leptin and platelet aggregation A Corsonello et al leptin is able to increase platelet-free calcium in a dosedependent manner, and that the inhibition of PLC completely abates the effect of leptin on both platelet aggregation and free calcium concentrations. These findings suggest that signaling pathways other than JAK-STAT tyrosine phosphorylation may be involved in mediating the prothrombotic action of leptin. Further studies in this field are required to clarify the role of leptin in the association between obesity and increased thrombotic risk in humans.
